Relay Therapeutics, Inc. (RLAY)
NASDAQ: RLAY · Real-Time Price · USD
9.44
-0.38 (-3.87%)
At close: Mar 24, 2026, 4:00 PM EDT
9.46
+0.02 (0.21%)
After-hours: Mar 24, 2026, 6:00 PM EDT
Relay Therapeutics Employees
Relay Therapeutics had 192 employees as of December 31, 2025. The number of employees decreased by 69 or -26.44% compared to the previous year.
Employees
192
Change
-69
Growth
-26.44%
Revenue / Employee
$79,974
Profits / Employee
-$1,439,995
Market Cap
1.69B
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 192 | -69 | -26.44% |
| Sep 30, 2025 | 188 | -106 | -36.05% |
| Jun 30, 2025 | 197 | -107 | -35.20% |
| Mar 31, 2025 | 259 | -50 | -16.18% |
| Dec 31, 2024 | 261 | -62 | -19.20% |
| Sep 30, 2024 | 294 | -49 | -14.29% |
| Jun 30, 2024 | 304 | -41 | -11.88% |
| Mar 31, 2024 | 309 | -19 | -5.79% |
| Dec 31, 2023 | 323 | -4 | -1.22% |
| Sep 30, 2023 | 343 | 23 | 7.19% |
| Jun 30, 2023 | 345 | 40 | 13.11% |
| Mar 31, 2023 | 328 | 52 | 18.84% |
| Dec 31, 2022 | 327 | 82 | 33.47% |
| Sep 30, 2022 | 320 | 88 | 37.93% |
| Jun 30, 2022 | 305 | 102 | 50.25% |
| Mar 31, 2022 | 276 | 113 | 69.33% |
| Dec 31, 2021 | 245 | 86 | 54.09% |
| Sep 30, 2021 | 232 | 100 | 75.76% |
| Jun 30, 2021 | 203 | 80 | 65.04% |
| Mar 31, 2021 | 163 | 41 | 33.61% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Sarepta Therapeutics | 835 |
| Ascentage Pharma Group International | 605 |
| Recursion Pharmaceuticals | 600 |
| Ocular Therapeutix | 325 |
| Zymeworks | 264 |
| Soleno Therapeutics | 182 |
| Aurinia Pharmaceuticals | 128 |
| Definium Therapeutics | 106 |
RLAY News
- 8 days ago - Relay Therapeutics' Cancer Drug Hits 11.1-Month Progression Free Survival - What Does This Means For Pretreated Breast Cancer Patients? - Benzinga
- 8 days ago - Relay Therapeutics Announces Data from Zovegalisib + Fulvestrant at the Phase 3 Dose of 400mg BID Fed at ESMO Targeted Anticancer Therapies Congress 2026 - GlobeNewsWire
- 13 days ago - Relay Therapeutics, Inc. (RLAY) Presents at Barclays 28th Annual Global Healthcare Conference Transcript - Seeking Alpha
- 18 days ago - Relay Therapeutics, Inc. (RLAY) Presents at TD Cowen 46th Annual Health Care Conference Transcript - Seeking Alpha
- 19 days ago - Relay Therapeutics: Breakthrough Designation Sets The Stage For A Key Zovegalisib Data Catalyst - Seeking Alpha
- 26 days ago - Relay Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Outlines Anticipated 2026 Milestones - GlobeNewsWire
- 4 weeks ago - Relay Therapeutics to Participate in Two Upcoming Investor Conferences in March - GlobeNewsWire
- 4 weeks ago - Relay Therapeutics to Announce Fourth Quarter and Full Year 2025 Financial Results and Corporate Highlights on February 26, 2026 - GlobeNewsWire